S E Kern
Impact in
- Oncology top 0.2%
- Pancreatic and Hepatic Oncology Research
- Cancer-related Molecular Pathways
- Cancer Research top 0.2%
- Cancer Genomics and Diagnostics
- MicroRNA in disease regulation
Papers in
- Oncology 25
- Pancreatic and Hepatic Oncology Research 18
- Cancer-related Molecular Pathways 4
- Colorectal Cancer Screening and Detection 3
-
- Cancer Genomics and Diagnostics 14
- Co-authors
- Ralph H. Hruban (17 shared papers)Bert Vogelstein (6 shared papers)Charles J. Yeo (15 shared papers)Michael Goggins (9 shared papers)Ralph H. Hruban (3 shared papers)Christopher A. Moskaluk (4 shared papers)Kenneth W. Kinzler (2 shared papers)Jason L. Parsons (2 shared papers)
- Journals
- Annals of Oncology (3 papers)JAMA (1 paper)Journal of Molecular Catalysis B Enzymatic (1 paper)Advances in experimental medicine and biology (1 paper)The Journal of Immunology (1 paper)
- Partner nations
- United StatesNetherlandsSlovenia
In The Last Decade
S E Kern
51 papers receiving 8.5k citations
S E Kern's Hit Papers
Peers
Comparison fields: 5 of 132
- Oncology 5.3k
- Cancer Research 2.7k
- Pathology and Forensic Medicine 1.3k
- Biotechnology 587
- Molecular Biology 4.2k
Countries citing papers authored by S E Kern
This map shows the geographic impact of S E Kern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S E Kern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S E Kern more than expected).
Fields of papers citing papers by S E Kern
This network shows the impact of papers produced by S E Kern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S E Kern. The network helps show where S E Kern may publish in the future.
Co-authors
The 25 scholars most cited alongside S E Kern, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Oncogenic forms of p53 inhibit p53-regulated gene expression Hit paper breakdown → | 1992 | 837 |
| 2 | Scrambled exons Hit paper breakdown → | 1991 | 789 |
| 3 | Progression model for pancreatic cancer. Hit paper breakdown → | 2000 | 689 |
| 4 | Tumor-suppressive pathways in pancreatic carcinoma. Hit paper breakdown → | 1997 | 574 |
| 5 | Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Hit paper breakdown → | 1996 | 515 |
| 6 | Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. | 2000 | 472 |
| 7 | p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. | 1994 | 380 |
| 8 | p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. | 1997 | 368 |
| 9 | Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. | 1994 | 319 |
| 10 | Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression. | 1998 | 277 |
| 11 | The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. | 2001 | 251 |
| 12 | 1989 | 243 | |
| 13 | Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. | 1998 | 240 |
| 14 | Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. | 2001 | 237 |
| 15 | Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. | 1998 | 211 |
| 16 | Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. | 2001 | 190 |
| 17 | Familial pancreatic cancer: a review. | 1996 | 188 |
| 18 | A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. | 2000 | 165 |
| 19 | Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. | 1998 | 151 |
| 20 | Microdissection and polymerase chain reaction amplification of genomic DNA from histological tissue sections. | 1997 | 144 |
About S E Kern
S E Kern is a scholar working on Oncology, Cancer Research, Molecular Biology, Pathology and Forensic Medicine and Epidemiology, having authored 51 papers that have together received 8.9k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (18 papers), Cancer Genomics and Diagnostics (14 papers), Genetic factors in colorectal cancer (12 papers), Neuroendocrine Tumor Research Advances (5 papers), Cancer-related Molecular Pathways (4 papers), Cancer Research and Treatments (4 papers), Neuroblastoma Research and Treatments (3 papers) and Colorectal Cancer Screening and Detection (3 papers). The work is most often cited by research in Oncology (5.3k citations), Cancer Research (2.7k citations), Pathology and Forensic Medicine (1.3k citations), Biotechnology (587 citations) and Molecular Biology (4.2k citations). S E Kern has collaborated with scholars based in United States, Netherlands and Slovenia. Frequent co-authors include Ralph H. Hruban, Bert Vogelstein, Charles J. Yeo, Michael Goggins, Ralph H. Hruban, Christopher A. Moskaluk, Kenneth W. Kinzler, Jason L. Parsons, Michael Goggins and Ralph H. Hruban. Their work appears in journals such as Annals of Oncology, JAMA, Journal of Molecular Catalysis B Enzymatic, Advances in experimental medicine and biology and The Journal of Immunology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.